Amicus Therapeutics — Q1 2024 Earnings Presentation
23 slides from Amicus Therapeutics's earnings presentation, May 9, 2024
Slide 1: 1Q24 Results Conference Call & Webcast
AT T H E F O R E F RO N T O F THERAPIES FOR RARE DISEASES 1Q24 Results Conference Call & Webcast May 9, 2024
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and c
Slide 3: A Rare Company
A Rare Company A leading biotech company projected to deliver 2024 total revenue growth of 25%-30%1 LEVERAGEABLE GLOBAL 2 World Class Clinical 25-30% APPROVED Development FY 2024 Total COMMERCIAL THERAPIES Capabilities Revenue Growth1 ORGANIZATION >500 EMPLOYEES 13-17% Guiding to Full Combined Peak
Slide 4: 2024 Strategic Priorities
2024 Strategic 1 ® Galafold revenue growth of 11-16% at CER1, now raised to 13-17% Priorities A Transformative 2 ® Execute multiple successful launches of Pombiliti + Opfolda ® Year Ahead for Amicus Advance ongoing studies to support medical and scientific 3 leadership in Fabry and Pompe diseases 4
Slide 5: Galafold (migalastat) Continued Growth
Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 5
Slide 6: 2024 Galafold Success (as of March 31, 2024)
2024 Galafold Success (as of March 31, 2024) Galafold is the only approved oral treatment option in Fabry disease A unique mechanism of action for Fabry patients with amenable variants $99.4M 1Q24 Galafold Revenue >60% 13-17% Share of Treated 2024 Galafold Amenable Patients Growth at CER1 2,400+ 35-
Slide 7: Galafold Performance
Galafold Performance Q1 2024 Galafold reported revenue growth of +16% at CER to $99.4M $438M-$454M1 $388M Global mix of switch (~42%) and previously untreated patients (~58%)2 $329M Q4 $306M $107M Expect non-linear quarterly growth to continue $261M due to uneven ordering patterns and FX Q3 fluc
Slide 8: Key Growth Drivers for 2024
Key Growth Drivers for 2024 Highest patient demand in last four years lays strong foundation for continued double-digit Galafold growth in 2024 Expanding market through uptake in naïve population as well as geographic and label expansion Increasing patient identification through ongoing medical
Slide 9: Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat)
Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Potential to establish a new standard of care for people living with late-onset Pompe disease 9
Slide 10: Pombiliti + Opfolda Performance
Pombiliti + Opfolda Performance Q1 2024 revenue of $11M, up +30% from Q4 2023, provides strong foundation for 2024 $62M-67M1 $11M Q1 $11M Q1 FY23 FY24 $81M Guiding to $62M to $67M in FY 2024 Pombiliti + Opfolda Revenue1 10 1At CER: Constant Exchange Rates
Slide 11: Successful Global Launch of Pombiliti + Opfolda Underway
Successful Global Launch of Pombiliti + Opfolda Underway Focus in 2024 is on maximizing the number of patients on therapy by year end Patient Demand KOL Outreach Access and As of end of April 2024 Reimbursement ~155 patients treated with Successfully engaged with Positive interactions commercial pro
Slide 12: Regulatory and Clinical Updates
Regulatory and Clinical Updates Continuing to build the body of evidence and expand commercial access >10 reimbursement dossiers and multiple regulatory submissions throughout 2024 Ongoing clinical studies in children with late-onset Pompe disease (LOPD) and infantile-onset Pompe disease (IOPD)
Slide 13: Corporate Outlook
Corporate Outlook Delivering on our mission for patients and shareholders 13
Slide 14: Q1 2024 Select Financial Results
Q1 2024 Select Financial Results Q1 2024 revenue of $110M, up 28% and net loss reduced (in thousands, except per share data) Mar. 31, 2024 Mar. 31, 2023 Product Revenue $110,403 $86,270 Cost of Goods Sold 13,567 6,942 R&D Expense 28,329 41,499 SG&A Expense 88,029 73,957 Changes in Fair Value of Cont
Slide 15: Updated Full-Year 2024 Guidance
Updated Full-Year 2024 Guidance Updated Guidance Previous Guidance Total Revenue Growth1 25% to 30% - Galafold Revenue Growth1 13% to 17% 11% to 16% Pombiliti + Opfolda Revenue1 $62M to $67M - Non-GAAP Operating Expense $345M to $365M $345M to $365M Guiding to full-year 2024 non-GAAP profitability 1
Slide 16: Positioned for Significant Value Creation in 2024
Positioned for Significant Value Creation in 2024 Unlocking the value of two unique commercial therapies in sizeable and growing markets Delivering Clear line of Accelerating sight to full-year total revenue generating non-GAAP1 growth positive profitability cashflow 16 1 Non-GAAP Net (Loss) Income
Slide 17: Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases
Ultimate Measure of Success: Impacting the Lives of People Living with Rare Diseases >350 Patients* >2,600 Patients* Many Thousands of Patients* YE17 YE23 2024+ 17 *Clinical and commercial, all figures approximate
Slide 18: Appendix
Amicus Therapeutics Appendix
Slide 19: Reconciliation of Non-GAAP Financial Measures: Operating Expenses
| Appendix | Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) (Unaudited) Three Months Ended March 31, 2024 2023 Total operating expenses - as reported GAAP $ 124,557 $ 116,964 Research and development: Stock-based compensation 4,871 8,490 Selling, general and a
Slide 20: Reconciliation of Non-GAAP Financial Measures: Net Loss
| Appendix " Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands, except share and per share amounts) (Unaudited) Three Months Ended March 31, 2024 2023 GAAP net loss S$ (48,419) $ (52,932) Share-based compensation 30,803 34,894 Changes in fair value of contingent c
Slide 21: Environmental, Social, & Governance (ESG) Snapshot
Environmental, Social, & Governance (ESG) Snapshot Who We Serve Environmental Our mission is to drive Diversity, Equity, & Management sustainability with our partners by Inclusion (DEI) Address a rare genetic disease Committed to producing incorporating Programs we Pledge to support a more inclusive
Slide 22: FX Sensitivity and Galafold Distribution of Quarterly Sales
FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q1 2024: Currency Variances: Q1 2023 Q1 2024 YoY Variance USD/ EUR 1.073 1.086 1.2% Distribution of Galafold Revenue GBP 1.215 1.268 4.4% by Quarter over Past 5 Years: JPY 0.008 0.007 (10.8%) Q1 Q2 Q3 Q4 5 Year
Slide 23: Streamlined Rare Disease Pipeline with Focus on Fabry and Pompe Franchises
Streamlined Rare Disease Pipeline with Focus on Fabry Disease and Pompe Disease Franchises INDICATION D I S C O V E R Y P R E C L I N I C A L P H A S E 1 / 2 P H A S E 3 R E G U L A T O R Y C O M M E R C I A L FAB RY F RANC H IS E Galafold® (migalastat) Fabry Genetic Medicines Next-Generation Chaper